Kennedy Edward Moore JR. Purchases Shares of Arvinas, Inc.
Kennedy Edward Moore JR. acquired 22,714 shares of Arvinas, Inc. on June 24, 2026.
Key Points
- Kennedy Edward Moore JR. bought 22,714 shares of Arvinas, Inc. (ARVN) on June 24, 2026.
- Arvinas, Inc. is a biotechnology company with a market cap of $518.1 million and a 52-week high of $14.51.
- Analysts from Stephens & Co. and Barclays have reiterated 'buy' ratings with price targets of $18 and $20, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kennedy Edward Moore JR. recently acquired 22,714 shares of Arvinas, Inc. (NasdaqGS: ARVN) on June 24, 2026. The transaction was not part of a planned trading program, indicating a direct purchase by the insider.
Insider Buying and Selling at Arvinas, Inc.
On June 24, 2026, several insiders, including Kennedy Edward Moore JR., made significant purchases of Arvinas shares. Bain Linda bought 22,714 shares, while Smaldone Alsup Laurie and Norwalk Leslie each acquired 15,527 shares. Morrison Briggs also made two purchases, totaling 38,241 shares.
Other Institutional Activity in Arvinas, Inc.
In recent institutional activity, BlackRock, Inc. trimmed its holdings by 524,917 shares, leaving it with 6,797,584 shares valued at about $72.1 million. Vanguard Portfolio Management LLC opened a new position with 3,889,628 shares worth approximately $41.2 million. D. E. Shaw & Co., Inc. reduced its stake by 50,634 shares, maintaining 3,638,567 shares valued at $38.6 million. TCG Crossover Management, LLC decreased its holdings by 278,755 shares, ending with 2,387,461 shares worth about $25.3 million.
Arvinas, Inc. Stock Down 12.9%
Shares of Arvinas, Inc. traded near $8.03 on Saturday. The biotechnology company has a market cap of $518.1 million. It is not currently profitable, so it has no meaningful forward P/E ratio. The stock's 52-week range spans from $6.06 to $14.51, with a 50-day moving average of $9.08 and a 200-day moving average of $10.67. Arvinas maintains a strong liquidity position with a current ratio of 5.44 and a quick ratio of 5.36.
$ARVN stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Arvinas reported revenue of $89.4 million with a decline in revenue growth of 91.7%. The company posted a net margin of -247.5% and a return on equity of -42.3%. Investors can look forward to the next earnings report on August 5, 2026.
Analysts Set New Price Targets
On June 3, 2026, Stephens & Co. reiterated its 'buy' rating on Arvinas with a price target of $18. Barclays maintained a 'buy' rating with a $20 target on May 13, 2026. BTIG also kept a 'buy' rating and set an $18 target. The analyst consensus suggests a 'buy' recommendation, with a mean price target of $14.8 across 15 analyst opinions.
About Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company based in New Haven, Connecticut. It focuses on developing therapies that degrade disease-causing proteins using its proprietary PROTAC technology. The company is working on various clinical development programs targeting neurodegenerative diseases and cancers. Arvinas collaborates with major pharmaceutical companies like Pfizer and Genentech.
Bottom Line
Kennedy Edward Moore JR.'s recent purchase of Arvinas shares highlights insider confidence in the company's potential. Arvinas, a player in the biotechnology sector, continues to attract attention with its innovative approach to protein degradation. While the company is not yet profitable, analysts remain optimistic about its future prospects, as reflected in recent 'buy' ratings.
Get Arvinas, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.